中国肾脏移植受者免疫抑制治疗指南(2023版)  

Chinese clinical practice guidelines for immunosuppressive therapy in kidney transplant recipients(2023 edition)

作　　者：中华医学会器官移植学分会 中国医疗保健国际交流促进会肾脏移植学分会 薛武军[2] 田普训[2] Branch of Organ Transplantation,Chinese Medical Association;Branch of Kidney Transplantation,China International Exchange and Promotive Association for Medical and Health Care;Xue Wujun;Tian Purun(不详;Department of Kidney Transplantation,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061)

机构地区：[1]不详 [2]西安交通大学第一附属医院肾移植科,西安710061

出　　处：《中华器官移植杂志》2024年第10期645-663,共19页Chinese Journal of Organ Transplantation

基　　金：国家自然科学基金(82270791)。

摘　　要：免疫抑制治疗是预防肾脏移植受者术后排斥反应的主要手段。为实现肾脏移植受者规范化应用免疫抑制剂,由中华医学会器官移植学分会发起制定《中国肾脏移植受者免疫抑制治疗指南(2023版)》。指南根据《牛津大学循证医学中心分级2009版》的证据分级与推荐意见强度标准制定,全面覆盖了肾脏移植受者诱导期、维持期及排斥反应时,免疫抑制剂的选择、剂量调整、使用方法及监测等共计20项关键临床议题。本指南参考了国内外关于肾脏移植免疫抑制剂使用的多个指南,同时兼顾中国肾脏移植临床现状,在之前的基础上融入了最新的临床试验证据,对用药方法进行精细化的阐述,为临床决策过程提供了更加详实、有力的循证支持。期望通过循证方法指导临床实践,促使我国肾脏移植受者更加科学、合理、个体化的应用免疫抑制剂,提高受者和移植肾的健康长期存活。Immunosuppressive therapy is a major mode of preventing rejection of kidney transplant(KT)recipients.To standardize the application of immunosuppressants for KT recipients,the Organ Transplantation Branch of Chinese Medical Association initiated the drafting of the Chinese clinical practice guidelines for immunosuppressive therapy in kidney transplant recipients(2023 edition).Based upon Oxford Centre for Evidence-Based Medicine 2009 Levels of Evidence,it has addressed 20 key clinical issues,including selecting,dosage adjusting,dosing and monitoring of immunosuppressants during induction,maintenance and rejection phases in KT recipients.Incorporating both international and domestic guidelines,it also took into account the current state of KT in China.Drawing upon previous versions,the Edition 2023 has integrated the latest clinical trial evidence and provided more detailed explanations of treatment protocols,offering stronger evidence-based supports for clinical decision-making.It was intended to guide clinical practice to promote more scientific,rational and individualized dosing of immunosuppressants in KT recipients,improving long-term wellbeing and survival of both recipients and grafted kidneys.

关 键 词：肾脏移植 免疫抑制剂 诱导期 维持期 排斥反应 

分 类 号：R699.2[医药卫生—泌尿科学]